7062.T
The company operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the development, production, and sale of pharmaceutical products.
Business. The company operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the development, production, and sale of pharmaceutical products.
The company's capital structure is characterized by a high debt-to-equity ratio of 3.96, indicating a significant reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.63, suggesting the company has sufficient short-term assets to cover its short-term liabilities, but with limited excess. The company's price-to-book ratio is 1.35, and its price-to-tangible-book ratio is also 1.35, indicating that the market value is slightly above the book value of tangible assets.
Profitability metrics show a challenging performance, with a negative return on equity of -15.79% and a negative return on assets of -2.81%. These figures are below the industry median for the Healthcare Facilities & Services industry, which typically exhibits positive returns on equity and assets. The company's operating income is negative at -106,196,000 JPY, and its net income is also negative at -244,548,000 JPY, indicating a loss-making position.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration increases the risk associated with the company's revenue streams, as it is heavily dependent on a single segment for its income.
The company's growth trajectory is uncertain, with no significant revenue growth reported in the most recent fiscal year. The company's operating cash flow is negative at -319,199,000 JPY, and its free cash flow is also negative at -177,514,000 JPY, indicating a lack of cash generation. The company's capital expenditure is -147,906,000 JPY, suggesting a reduction in investment in long-term assets.
The company's risk assessment indicates a medium liquidity risk, with a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential reported. The company's financial position is further complicated by its high debt levels, which could limit its ability to respond to market changes or invest in growth opportunities.
Recent events, as disclosed in the company's financial statements, include a negative earnings per share (EPS) of -103.65 JPY and a revenue of 7,582,580,000 JPY. These figures indicate a challenging financial performance, with the company reporting a loss in the most recent fiscal period.
- The company is operating at a loss, with negative operating and net income.
- The company has a high debt-to-equity ratio, indicating a significant reliance on debt financing.
- The company's liquidity position is medium, with a current ratio of 1.63.
- The company's profitability metrics are negative, with a return on equity of -15.79% and a return on assets of -2.81%.
- The company's revenue is concentrated in a single business segment, increasing the risk associated with its revenue streams.
- The company's growth trajectory is uncertain, with no significant revenue growth reported in the most recent fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 7062.T Market data — financials · 2026-05-27
- Fureasu Co Ltd Market data — analyst estimates · 2026-05-27